

**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Lawrence B. Bugaisky
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Hevey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Albert L. Ferro*
Donald R. Banowitz
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Brian J. Del Buono
Virgil Lee Beaton
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhulier

Rae Lynn P. Guest
George S. Bardmesser
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Aric W. Ledford
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle*
Gaby L. Longsworth
Lori A. Gordon
Nicole D. Dretar
Ted J. Ebersole
Jyoti C. Iyer

Laura A. Vogel
Michael J. Mancuso
Bryan S. Wade
Aaron L. Schwartz
Michael G. Penn*
Matthew E. Kelley*
Shannon A. Carroll*
Nicole R. Kramer*

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford

Michelle K. Holoubek
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Christopher J. Walsh
Liliana Di Nola-Baron
Peter A. Socarras

Of Counsel

Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

April 13, 2005

WRITER'S DIRECT NUMBER:
(202) 772-8528

INTERNET ADDRESS:
DKLEIN@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/630,763; Filed: July 31, 2003
For: **Aminoalkyl-Substituted Aryl Compounds and Their Use as Sodium
Channel Blockers**
Inventors: SUN *et al.*
Our Ref: 1861.1460001

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Second Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
2. Form PTO-1449 (2 pages) listing six (6) cited documents;
3. Copies of five (5) cited documents: AP2, AR3, AS3, AT3 and AL3; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned for.

Commissioner for Patents
April 13, 2005
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Daniel A. Klein", written in a cursive style.

Daniel A. Klein
Attorney for Applicants
Registration No. 54,225

JMC/DAK:trh
Enclosures

386389-1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SUN *et al.*

Appl. No.: 10/630,763

Filed: July 31, 2003

For: **Aminoalkyl-Substituted Aryl
Compounds and Their Use as Sodium
Channel Blockers**

Confirmation No.: 8454

Art Unit: 1626

Examiner: Shameem, G.M.

Atty. Docket: 1861.1460001

**Second Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on March 9, 2004, in connection with the above-captioned application.

Copies of documents **AP2**, **AL3**, and **AR3-AT3** are submitted herewith. However, in accordance with 37 C.F.R. § 1.98(a)(2), a copy of the U.S. patent, document **AK1**, cited on the attached Form PTO-1449, is not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document **AP2** cited on Form PTO 1449:

Document **AP2**, CS 272 944 B1, is written in a foreign language. An English language abstract is attached as document **AT3**. Document **AP2** appears to describe 2-(substituted phenylthio)benzylamines with antimicrobial activity.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.


This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Daniel A. Klein
Attorney for Applicants
Registration No. 54,225

Date: April 13, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

ATTY. DOCKET NO.
1861.1460001APPLICATION NO.
10/630,763

FORM PTO-1449

FIRST NAMED INVENTOR
Qun SUNFILING DATE
July 31, 2003ART UNIT
1626SECOND SUPPLEMENTAL
PRIORITY INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AL						
	AK1	4,247,550	01/27/1981	Feit <i>et al.</i>			12/21/1977

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP2	CS 272 944 B1	12/16/1991	Czechoslovakia			Yes X No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>3</u>	Liu, G., <i>et al.</i> , "Discovery of Novel p-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 1. Identification of an Additional Binding Pocket Based on an Anilino Diaryl Sulfide Lead," <i>J. Med. Chem.</i> 43:4025-4040, American Chemical Society (2000)
	AS	<u>3</u>	Kmoníček, V., <i>et al.</i> , "Potential Antidepressants: 2-(Fluoro-, Chloro-, Bromo- and Cyanophenylthio)benzylamines as Inhibitors of 5-Hydroxytryptamine and Noradrenaline Re-Uptake in Brain," <i>Collect. Czech. Chem. Commun.</i> 56:2468-2481, Institute of Organic Chemistry and Biochemistry (1991)
	AT	<u>3</u>	STN Easy Database, Accession No. 1992:612134, English language abstract for CS 272 944 B1, document AP2

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

ATTY. DOCKET NO.

861.1460001

APPLICATION NO.

10/630,763

FIRST NAMED INVENTOR

Qun SUN

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

FILING DATE

July 31, 2003

ART UNIT

1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL3	WO 01/14331 A2	03/01/2001	WIPO			Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.